Most regenerative medicine companies are entirely dependent on external funding to sustain their research. BICC is structured differently — our health services and infrastructure businesses generate operating revenue today, funding the EV science platform without diluting the mission or the timeline.

​

The result is a platform that can move at the pace of science, not the pace of fundraising — advancing Extracellular Vesicle technology from cosmeceuticals to clinical applications, anchored by a signed Research Collaboration Agreement with A*STAR, Singapore's national research agency.